The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kozlovskaia L.V.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova

Bobkova I.N.

Otdel nefrologii NII uronefrologii i reproduktivnogo zdorov'ia cheloveka Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

Nanchikeeva M.L.

Oblastnaia klinicheskaia bol'nitsa, Vladimir

Chebotareva N.V.

Medical University «Russian University of Friendship of Peoples» Ministry of Health of the Russian Federation, Moscow, Russia, 117198

Li O.A.

Otdel nefrologii NII uronefrologii i reproduktivnogo zdorov'ia cheloveka Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

Plieva O.K.

Kafedra nefrologii i gemodializa FPPOV Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

General molecular and cellular mechanisms for renal and cardiac remodeling in chronic kidney disease: a target for nephrocardioprotection

Authors:

Kozlovskaia L.V., Bobkova I.N., Nanchikeeva M.L., Chebotareva N.V., Li O.A., Plieva O.K.

More about the authors

Journal: Therapeutic Archive. 2013;85(6): 66‑72

Views: 1285

Downloaded: 297

Download PDF (RU)
Contact the author
Table of contents

GENERAL MOLECULAR AND CELLULAR MECHANISMS FOR RENAL AND CARDIAC REMODELING IN CHRONIC KIDNEY DISEASE: A TARGET FOR NEPHROCARDIOPROTECTION
GENERAL MOLECULAR AND CELLULAR MECHANISMS FOR RENAL AND CARDIAC REMODELING IN CHRONIC KIDNEY DISEASE: A TARGET FOR NEPHROCARDIOPROTECTION

To cite this article:

Kozlovskaia LV, Bobkova IN, Nanchikeeva ML, Chebotareva NV, Li OA, Plieva OK. General molecular and cellular mechanisms for renal and cardiac remodeling in chronic kidney disease: a target for nephrocardioprotection. Therapeutic Archive. 2013;85(6):66‑72. (In Russ.)

МСФ на ЯМ
Close metadata
Recommended articles:
The effect of ethy­lmethylhydroxypyridine succinate on the para­meters of chro­nic neuroinflammation and plastic processes in the brain of old rats during course of dexa­methasone admi­nistration. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(9):115-121
Loca­lization features of FAP-positive acti­vated stro­mal cells in fibrosis in patients with new coro­navirus infe­ction COVID-19. Russian Journal of Archive of Pathology. 2024;(6):5-14

The lecture considers a number of molecular and cellular mechanisms underlying the structural and functional rearrangement and development of renal and cardiac fibrosis in chronic kidney disease (CKD). It details the key component of disadaptative organ remodeling (the formation of myofibroblasts via epithelial-mesenchymal and endothelial-mesenchymal transdifferentiation) and the role of leading angiofibrogenic mediators (angiotensin II, transforming growth factor-Β type 1, a plasminogen activator inhibitor type 1, etc.) in the regulation of these processes. Investigation of the molecular and cellular bases of organ fibrosis, including the factors of dysregulated activation, differentiation and survival of microfibroblasts, makes it possible to specify the mechanisms of action of traditional nephro- and cardioprotective agents, to offer a possibility for a goal-oriented (target) effect on individual fibrogenic components, and to expand the arsenal of medications suppressing renal and cardiac remodeling.

Keywords:

cardiac fibrosis
nephrofibrosis
epithelial-mesenchymal transdifferentiation
endothelial-mesenchymal transdifferentiation
myofibroblasts
angiotensin II
plasminogen activator inhibitor
transforming growth factor-Β1
vascular endothelial growth factor
cardio- and nephroprotection

Authors:

Kozlovskaia L.V.

Pervyĭ Moskovskiĭ gosudarstvennyĭ meditsinskiĭ universitet im. I.M. Sechenova

Bobkova I.N.

Otdel nefrologii NII uronefrologii i reproduktivnogo zdorov'ia cheloveka Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

Nanchikeeva M.L.

Oblastnaia klinicheskaia bol'nitsa, Vladimir

Chebotareva N.V.

Medical University «Russian University of Friendship of Peoples» Ministry of Health of the Russian Federation, Moscow, Russia, 117198

Li O.A.

Otdel nefrologii NII uronefrologii i reproduktivnogo zdorov'ia cheloveka Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

Plieva O.K.

Kafedra nefrologii i gemodializa FPPOV Pervogo MGMU im. I.M. Sechenova Minzdrava Rossii

List of references:

  1. Kalluri R., Neilson E.G. Epithelial-mesenchymal transitition and its implication for fibrosis. J Clin Invest 2003; 112 (12): 1776-1784.
  2. Yoshimatsu Y., Watabe T. Role of TGF-Β1 signals in endothelial-mesenchymal transitition in cardiac fibrosis. Intern J Inflam 2011;2011:724080. doi: 10.4061/2011/724080. Epub 2011 Nov 30.
  3. Zeisberg M., Neilson E.G. Biomarkers for epithelial-to-mesenchymal transitition. J Clin Invest 2009; 119 (6): 1429-1437.
  4. Leask A. Potential therapeutic targets for cardiac fibrosis: TGF-Β, angiotensin, endothelin, CCN2 and PDGF? Partners of fibroblast activation. Circul Res 2010; 106 (11): 1675-1680.
  5. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12.
  6. Eddy A.A., Fogo A.V. Plasminogen activator inhibitor-1in chronic kidney disease: evidence and mechanisms of action. J Am Soc Nephrol 2006; 17: 2999-3012.
  7. Takeda N., Manabe I. Cellular interplay between cardiomyocytes and nonmyocytes in cardiac remodeling. Intern J Inflam 2011; 2011: 535241. doi: 10.4061/2011/535241. Epub 2011 Sep 18.
  8. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009; 123: 255-278.
  9. Zeisberg E.M., Tarnavski O., Zeisberg M. et al. Endothelial-to-mesenchymal transitition contributes to cardiac fibrosis. Nature Med 2007; 13 (8): 952-961.
  10. Liu Y. New insights into epithelial-mesenchymal transitition contribute in kidney fibrosis. J Am Soc Nephrol 2010; 21: 212-222.
  11. Zeisberg E.M., Kalluri R. Epithelial-to-mesenchymal transitition contributes in renal fibrosis. J Molecul Med 2004; 82 (3): 175-181.
  12. Kriz W., Greitz N., Lemley K.V. Progression of glomerular diseases: is the podocyte the culprit? Kidney Int 1998; 54: 687-697.
  13. Lemley K.V., Lafayette A., Safai G. et al. Podocytopenia and disease severity in IgA nephropathy. Kidney Int 2002; 61: 1475-1485.
  14. Galichon P., Hertig A. Epithelial to mesenchymal transitition a biomarker in renal fibrosis: are we ready for bedside? Fibrogenes Tissue Repair 2011; 4: 11-17.
  15. Kriz W., Kaissling B., Le Hir M. Epithelial-mesenchymal transitition in kidney fibrosis: fact or fantasy? J Clin Invest 2011; 121: 468-472.
  16. Mukhin N.A., Kozlovskaya L.V., Bobkova I.N. i dr. Indutsiruemye proteinuriei mekhanizmy remodelirovaniya tubulointerstitsiya i vozmozhnosti nefroprotektsii pri glomerulonefrite. Vestn RAMN 2005; 1: 3-8.
  17. Kozlovskaya L.V., Bobkova I.N., Plieva O.K. i dr. Znachenie issledovaniya v moche molekulyarnykh mediatorov immunnogo vospaleniya i fibroza v pochke pri khronicheskom glomerulonefrite. Ter arkh 2004; 9: 84-87.
  18. Nanchikeeva M.L., Konechnaya E.Ya., Bulanov M.N. i dr. Vozmozhnosti rannei diagnostiki porazheniya pochek u bol'nykh gipertonicheskoi bolezn'yu. Ter arkh 2004; 9: 29-34.
  19. Bobkova I.N., Chebotareva N.V., Kozlovskaya L.V. i dr. Ekskretsiya s mochoi monotsitarnogo khemotaksicheskogo proteina-1 i transformiruyushchego faktora rosta Β1 kak pokazatel' progressirovaniya khronicheskogo glomerulonefrita. Ter arkh 2006; 5: 9-14.
  20. Schrijvers B.F., Flyvbjerg A., De Vriese A.S. The role of vascular endothelial growth factor (VEGF) in renal pathophysiology. Kidney Int 2004; 65 (6): 2003-2017.
  21. Fogo A.B., Kon V. The glomerulus - a view from the inside-the endothelial cell. Int J Biochem Cell Biol 2010; 42 (9): 1388-1397.
  22. Li O.A., Bobkova I.N., Kozlovskaya L.V. Klinicheskoe znachenie opredeleniya matriksnykh metalloproteinaz i ikh ingibitorov v moche bol'nykh khronicheskim glomerulonefritom. Ter arkh 2009; 8: 10-14.
  23. Li O., Bobkova I., Kozlovskaya L., Varshavskiy V. Matrix metalloproteinases (MMP) and its inhibitors in chronic glomerulonephritis (CGN): association with clinical activity and proteinuric remodeling of renal tubulointerstitium. Nephrol Dial Transplant Plus 2010; 1 (3): 375.
  24. Cheng S., Lovett D.H. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol 2003; 162: 1937-1949.
  25. Fogo A.B. The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis. Am J Kidney Dis 2000; 35: 179-188.
  26. Ruiz-Ortega M., Ruperez M., Esteban V. et al. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney disease. Nephrol Dial Transplant 2006; 21: 16-20.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.